Dr Andrew Teasdale


Andrew Teasdale PhD has 30 years’ experience in the pharmaceutical industry as an analytical chemist and within quality assurance and regulatory roles. In his current role he chairs AstraZeneca’s Impurity Advisory Group. Dr Teasdale has published a number of papers relating to mutagenic impurities, N Nitrosamines, extractables and leachables,  and other impurity related matters.  He is currently the chair of the  Extractables and Leachables safety Information exchange (ELSIE) and also led a number of industry expert groups; these include both safety and quality groups within Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), Product Quality Research Institute (PQRI) .  Andrew has also represented EFPIA in ICH Q3C, Q3D and Q3E Expert working groups. He has also advanced a number of key scientific advancements in the control of impurities as the inventor of the purge factor concept and the instigator of the development of Elemental Impurities database for excipients.

With over 50 scientific papers, he has also written 3 books:

Genotoxic Impurities – Strategies for Identification and control. Editor A Teasdale. Publisher Wiley. ISBN 978-0-470-49919-1

ICH Quality Guidelines – An Implementation Guide. Editors A Teasdale, D Elder, R W Nims. Publisher Wiley.  ISBN 978-1-118-97111-6.

Mutagenic Impurities – Strategies for Identification and Control Second Edition.  Editor A Teasdale. Publisher Wiley. ISBN 978-1-119-55121-8

Contact Andrew Teasdale